Life Sciences

Transactional Practice

Leaders

Ryan A. Murr San Francisco
View Profile

Overview

​Gibson Dunn's transactional lawyers have handled U.S. and international public and private mergers and acquisitions for companies in the life sciences sector and have provided counseling on financings, securities offerings, corporate governance, licensing and other collaborations.  Combined with our exceptional securities regulatory strength, we have breadth and insight that few firms can match in transactions including:  

  • Public and private debt and equity offerings
  • Stock and asset acquisitions
  • Public and private mergers
  • Private equity and leveraged buyouts  

Our clients range from large pharmaceutical companies to small biotechnology companies and include investment banks that serve as financial advisors to life sciences companies on significant acquisitions, as well as private equity funds, hedge funds and venture funds providing capital to these transactions.       

Mergers & Acquisitions

Gibson Dunn's life sciences and mergers and acquisitions lawyers regularly represent both buyers and sellers in transactions of all sizes, navigating business and legal issues effectively and efficiently.

Our life sciences M&A lawyers operate with a collaborative approach, working closely with colleagues in adjacent areas, such as FDA regulatory, intellectual property, tax, antitrust, health care, employment and employee benefits.  By providing a fully integrated team and working closely together, our M&A practitioners are able to manage our clients' needs and present solutions to issues often before they are identified by our clients.  Additionally, given that we represent both buyers and sellers, we are able to understand the perspective of both sides in M&A transactions and effectively manage many issues to ensure a smooth transaction.   

Capital Markets

Gibson Dunn's Capital Markets Practice Group advises life sciences clients in capital-raising transactions across the debt/equity continuum.  Our experience includes IPOs, follow-on equity offerings, convertible, high-yield and investment-grade debt, preferred stock and hybrid securities.  We also regularly advise clients in connection with:   

  • Shelf registrations
  • PIPEs and other private placements
  • Registered direct offerings
  • Exchange offers
  • Rights offerings
  • Warrant transactions
  • "At the market" equity offerings
  • Medium-term note programs
  • Subsidiary carve-outs
  • Spin-offs and split-offs
  • Special purpose acquisition companies (SPACs)
  • Liability management transactions such as debt tenders and consent solicitations

With an extensive representation of issuers and underwriters, combined with our exceptional securities regulatory strength, we provide comprehensive service, practiced judgment and deep understanding of the issues involved.

Licensing and Joint Ventures

Gibson Dunn lawyers represent life sciences clients in a wide variety of U.S. and international transactions involving the licensing, acquisition, development, marketing and distribution of intellectual property, including co-development and joint venture agreements.

A significant aspect of our licensing practice includes patent licensing, such as: 

  • Cross-licenses
  • Licenses granted by patent pools or industry consortia
  • Licenses granted as part of a strategic licensing program 
  • Licenses arising out of the settlement of litigation

We couple our experience in the pharmaceutical, medical device and biotechnology industries with our extensive IP knowledge to ensure that our clients enter into appropriate licensing transactions that protect their intellectual property rights.